PaxVax develops vaccines for infectious diseases in what the privately held company calls a "socially responsible' manner. It reports having raised more than $200 million from investors. This includes $105 million in December from Cerberus Capital Management, which is the majority owner.
Sunday, February 7, 2016
for protection wherever you are and wherever you go
PaxVax is a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases.